Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.

@article{Dezellus2017ProspectiveEO,
  title={Prospective evaluation of serum anti-M{\"u}llerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer.},
  author={A Dezellus and Paul Barri{\`e}re and Mario Campone and Claire Lemanski and Laurence Vanlemmens and Laurent Mignot and Thierry Delozier and Christelle L{\'e}vy and Claude Bendavid and Marc Debled and Thomas Bachelot and Christelle Jouannaud and Catherine Loustalot and Marie-Ange Mouret-Reynier and A Gallais-Umbert and Damien Masson and Thomas Freour},
  journal={European journal of cancer},
  year={2017},
  volume={79},
  pages={72-80}
}
AIM Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy. Fertility issues are of great concern for them. However, little is known on ovarian damage during chemotherapy and its evolution during long-term follow-up. The aim of this study was to provide a detailed description of serum anti-Müllerian hormone (AMH) evolution during chemotherapy and 24-month follow-up. METHODS This prospective cohort study was conducted in 250 patients, aged 18-39 years… CONTINUE READING